HOUSE-WELLNESS-FOODS
3.5.2016 13:51:54 CEST | Business Wire | Press release
A study from Japan has shown for the first time that heat-treated lactobacillus, as found in House Wellness Foods Feed LP20®, is effective in supporting the immune system of the Whiteleg shrimp, reversing disease trends and increasing reproduction. The study, published in the International Journal of Scientific and Research Publications , Volume 6, Issue 3, March 2016, is welcome news for the East Asian fishing industry, which has been plagued by vibriosis, linked to the presence of Vibrio parahaemolyticus and other bacteria found in salt water. Feed LP20® is proven safe, and represents groundbreaking evidence of the effectiveness of heat-treated lactobacillus, as measured in conjunction with this crucial species.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160503005537/en/
Feed LP20® was developed for livestock and fisheries as an alternative to antibiotic regimens, and as a functional product for improving immune function and productivity. It contains 20% heat-killed Lactobacillus plantarum L-137 (HK L-137) . Heat treatment of HK L-137, the central ingredient of House Wellness Foods’ Feed LP20® and Immuno-LP20® , is key to those products’ effectiveness, making them stable long-term at varying temperatures, easily handled, even under pressure, and maintaining immunostimulant properties while resisting degradation by water and gastric acids.
HWF is regarded as a pioneer in the continuous study of HK L-137, and Immuno-LP20 has been hugely successful as an immunobiotic, enjoying prominence among health-conscious consumers in the U.S. and worldwide as a natural aid to the body’s innate ability to defend itself against seasonal illness and allergy.
A joint study conducted in cooperation with Vietnam’s Can Tho University proved conclusively that the addition of as little as 100 ppm of Feed LP20 boosts immune function in the shrimp population and improves survival and growth rates, which were significantly (P<0.05) higher compared to other feeds. Immune parameters consisted of total haemocyte count, differential haemocyte count, phenoloxidase activity, phagocytic activity and clearance efficiency. The study also showed a critical synergistic effect in conjunction with B-glucan, an activator of immune system functions in aquaculture.
House Wellness Foods is pursuing sales and promotion of Feed LP20 for livestock and aquaculture in support of these industries and in the hope of ameliorating the blight of worldwide hunger.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160503005537/en/
Contact:
House Wellness Foods
Onoda Satoru, +81-3-5211-7220
Onoda_Satoru@house-wf.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian Expands Agent Trust Partner Ecosystem with Akamai to Advance Trusted AI Driven Commerce15.5.2026 15:00:00 CEST | Press release
Collaboration strengthens secure, scalable agentic commerce and supports emerging Know Your Agent standards Experian today announced that Akamai Technologies has joined its growing partner ecosystem, designed to further advance secure, trusted AI driven commerce through the Experian Agent Trust™ framework, alongside partner Skyfire supporting emerging payment innovation. As AI agents begin to search, decide, and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer directly initiated by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust is designed to address this challenge by establishing identity, accountability, and trust in agent driven interactions. “Trust, security, and performance must scale alongside the growing role of AI agents in digital commerce,” said Kathleen Peters,
The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 2615.5.2026 14:00:00 CEST | Press release
LYCRA FUSION™ Fiber for Personal Care Applications Debuts The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260515514441/en/ Join The LYCRA Company and Dukane at INDEX™ 26 in Geneva, as they showcase their latest advances in ultrasonic bonding for nonwovens, including new LYCRA FUSION™ fiber for personal care that delivers superior snapback. Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrason
Vecima to Highlight Next-Generation 50G-PON, DOCSIS® 4.0 vCMTS, AI & Automation, and Monetizable Streaming at ANGA COM 202615.5.2026 13:45:00 CEST | Press release
Vecima Networks Inc. (TSX: VCM) will highlight its leadership in next-generation broadband at ANGA COM 2026, showcasing AI-powered network operations, cloud-native DOCSIS® 4.0 access, and scalable fiber solutions. Anchored by the Entra® vCMTS platform, Automation, and All-PON™ innovations, Vecima is enabling operators to automate operations, improve reliability, and accelerate the evolution to converged cable and fiber networks. Delivering on Next-Generation PON With Entra All-PON™, Vecima is enabling future-ready fiber networks with a straightforward migration path from today’s 10G technologies to 50G-PON, ensuring long-term scalability and investment protection. The new Entra EPS1650 All-PON Shelf supports 50G-PON, XGS-PON, 10G-EPON, GPON, and EPON services. As a follow-on to Vecima's industry-first demonstration of a single port supporting 50G ITU PON and 10G-EPON in a Remote OLT, the EPS1650 brings that same single-port investment-protection path to GPON and XGS-PON operators in a
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
